ADA2 deficiency complicated by EBV-driven lymphoproliferative disease
Copyright © 2020 Elsevier Inc. All rights reserved..
A 29-year old male with recurrent respiratory and skin infections, anaemia and neutropaenia during childhood required immunoglobulin replacement for antibody deficiency from age 16. He remained relatively well until age 28 when he presented with a two-week history of fatigue, sore throat, fever and productive cough. He was found to have EBV viraemia and splenomegaly and a diagnosis of EBV-driven lymphoproliferative disease was made following bone marrow trephine. Family history was notable with three siblings: a healthy sister and two brothers with anaemia and neutropaenia; one who succumbed to septicaemia secondary to neutropaenic enterocolitis age 5 and another who developed intestinal vasculitis and antibody deficiency and had a successful haemopoetic stem cell transplant. The proband's DNA underwent targeted sequencing of 279 genes associated with immunodeficiency (GRID panel). The best candidates were two ADA2 variants, p.Arg169Gln (R169Q) and p.Asn370Lys (N370K). Sanger sequencing and co-segregation of variants in the parents, unaffected sister and all three affected brothers was fully consistent with compound heterozygous inheritance. Subsequent whole genome sequencing of the proband identified no other potential causal variants. ADA2 activity was consistent with a diagnosis of ADA2 deficiency in affected family members. This is the first description of EBV-driven lymphoproliferative disease in ADA2 deficiency. ADA2 deficiency may cause susceptibility to severe EBV-induced disease and we would recommend that EBV status and viral load is monitored in patients with this diagnosis and allogeneic SCT is considered at an early stage for patients whose ADA2 deficiency is associated with significant complications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:215 |
|---|---|
| Enthalten in: |
Clinical immunology (Orlando, Fla.) - 215(2020) vom: 01. Juni, Seite 108443 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Staples, Emily [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.01.2021 Date Revised 17.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clim.2020.108443 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309373530 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309373530 | ||
| 003 | DE-627 | ||
| 005 | 20231225133753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clim.2020.108443 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM309373530 | ||
| 035 | |a (NLM)32353633 | ||
| 035 | |a (PII)S1521-6616(20)30034-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Staples, Emily |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ADA2 deficiency complicated by EBV-driven lymphoproliferative disease |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2021 | ||
| 500 | |a Date Revised 17.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a A 29-year old male with recurrent respiratory and skin infections, anaemia and neutropaenia during childhood required immunoglobulin replacement for antibody deficiency from age 16. He remained relatively well until age 28 when he presented with a two-week history of fatigue, sore throat, fever and productive cough. He was found to have EBV viraemia and splenomegaly and a diagnosis of EBV-driven lymphoproliferative disease was made following bone marrow trephine. Family history was notable with three siblings: a healthy sister and two brothers with anaemia and neutropaenia; one who succumbed to septicaemia secondary to neutropaenic enterocolitis age 5 and another who developed intestinal vasculitis and antibody deficiency and had a successful haemopoetic stem cell transplant. The proband's DNA underwent targeted sequencing of 279 genes associated with immunodeficiency (GRID panel). The best candidates were two ADA2 variants, p.Arg169Gln (R169Q) and p.Asn370Lys (N370K). Sanger sequencing and co-segregation of variants in the parents, unaffected sister and all three affected brothers was fully consistent with compound heterozygous inheritance. Subsequent whole genome sequencing of the proband identified no other potential causal variants. ADA2 activity was consistent with a diagnosis of ADA2 deficiency in affected family members. This is the first description of EBV-driven lymphoproliferative disease in ADA2 deficiency. ADA2 deficiency may cause susceptibility to severe EBV-induced disease and we would recommend that EBV status and viral load is monitored in patients with this diagnosis and allogeneic SCT is considered at an early stage for patients whose ADA2 deficiency is associated with significant complications | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ADA2 | |
| 650 | 4 | |a Antibody deficiency | |
| 650 | 4 | |a EBV | |
| 650 | 4 | |a Immunodeficiency | |
| 650 | 4 | |a Lymphoproliferative disease | |
| 650 | 4 | |a Viraemia | |
| 650 | 7 | |a Intercellular Signaling Peptides and Proteins |2 NLM | |
| 650 | 7 | |a ADA2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.5.4.4 |2 NLM | |
| 650 | 7 | |a Adenosine Deaminase |2 NLM | |
| 650 | 7 | |a EC 3.5.4.4 |2 NLM | |
| 700 | 1 | |a Simeoni, Ilenia |e verfasserin |4 aut | |
| 700 | 1 | |a Stephens, Jonathan C |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Hana Lango |e verfasserin |4 aut | |
| 700 | 0 | |a NIHR-BioResource |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Penny |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, E Graham |e verfasserin |4 aut | |
| 700 | 1 | |a Javid, Babak |e verfasserin |4 aut | |
| 700 | 1 | |a Gkrania-Klotsas, Effrossyni |e verfasserin |4 aut | |
| 700 | 1 | |a Gattens, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Firth, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Shamardina, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Deevi, Sri V V |e verfasserin |4 aut | |
| 700 | 1 | |a Prapa, Matina |e verfasserin |4 aut | |
| 700 | 1 | |a Uttenthal, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Kumararatne, Dinakantha |e verfasserin |4 aut | |
| 700 | 1 | |a Thaventhiran, James E D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical immunology (Orlando, Fla.) |d 1999 |g 215(2020) vom: 01. Juni, Seite 108443 |w (DE-627)NLM098196855 |x 1521-7035 |7 nnns |
| 773 | 1 | 8 | |g volume:215 |g year:2020 |g day:01 |g month:06 |g pages:108443 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clim.2020.108443 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 215 |j 2020 |b 01 |c 06 |h 108443 | ||